BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33513792)

  • 1. Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions.
    Snodgrass RO; Chico TJA; Arthur HM
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33513792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on preclinical models of hereditary haemorrhagic telangiectasia: Insights into disease mechanisms.
    Arthur HM; Roman BL
    Front Med (Lausanne); 2022; 9():973964. PubMed ID: 36250069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models.
    Ruiz S; Zhao H; Chandakkar P; Papoin J; Choi H; Nomura-Kitabayashi A; Patel R; Gillen M; Diao L; Chatterjee PK; He M; Al-Abed Y; Wang P; Metz CN; Oh SP; Blanc L; Campagne F; Marambaud P
    J Clin Invest; 2020 Feb; 130(2):942-957. PubMed ID: 31689244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models of Hereditary Hemorrhagic Telangiectasia.
    Hwan Kim Y; Vu PN; Choe SW; Jeon CJ; Arthur HM; Vary CPH; Lee YJ; Oh SP
    Circ Res; 2020 Oct; 127(9):1122-1137. PubMed ID: 32762495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP10 functions independently from BMP9 for the development of a proper arteriovenous network.
    Choi H; Kim BG; Kim YH; Lee SJ; Lee YJ; Oh SP
    Angiogenesis; 2023 Feb; 26(1):167-186. PubMed ID: 36348215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
    Karlsson T; Cherif H
    Ups J Med Sci; 2018 Sep; 123(3):153-157. PubMed ID: 30251589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
    Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
    Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.
    Mahmoud M; Borthwick GM; Hislop AA; Arthur HM
    Lab Invest; 2009 Jan; 89(1):15-25. PubMed ID: 19015642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
    Pawlikowska L; Nelson J; Guo DE; McCulloch CE; Lawton MT; Young WL; Kim H; Faughnan ME;
    Am J Med Genet A; 2015 Jun; 167(6):1262-7. PubMed ID: 25847705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Executive summary of the 14th HHT international scientific conference.
    Ola R; Hessels J; Hammill A; Friday C; Clancy M; Al-Samkari H; Meadows S; Iyer V; Akhurst R
    Angiogenesis; 2023 Aug; 26(Suppl 1):27-37. PubMed ID: 37695357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations.
    Balachandar S; Graves TJ; Shimonty A; Kerr K; Kilner J; Xiao S; Slade R; Sroya M; Alikian M; Curetean E; Thomas E; McConnell VPM; McKee S; Boardman-Pretty F; Devereau A; Fowler TA; Caulfield MJ; Alton EW; Ferguson T; Redhead J; McKnight AJ; Thomas GA; ; Aldred MA; Shovlin CL
    Am J Med Genet A; 2022 Mar; 188(3):959-964. PubMed ID: 34904380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
    Latif MA; Sobreira NLD; Guthrie KS; Motaghi M; Robinson GM; Shafaat O; Gong AJ; Weiss CR
    Am J Med Genet A; 2021 Jul; 185(7):1981-1990. PubMed ID: 33768677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational and clinical spectrum of Japanese patients with hereditary hemorrhagic telangiectasia.
    Kitayama K; Ishiguro T; Komiyama M; Morisaki T; Morisaki H; Minase G; Hamanaka K; Miyatake S; Matsumoto N; Kato M; Takahashi T; Yorifuji T
    BMC Med Genomics; 2021 Dec; 14(1):288. PubMed ID: 34872578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
    Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
    Tillet E; Bailly S
    Front Genet; 2014; 5():456. PubMed ID: 25620979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and mutations in the ENG, ACVRL1, and SMAD4 genes in Korean patients with hereditary hemorrhagic telangiectasia.
    Lee ST; Kim JA; Jang SY; Kim DK; Do YS; Suh GY; Kim JW; Ki CS
    J Korean Med Sci; 2009 Feb; 24(1):69-76. PubMed ID: 19270816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.
    Ardelean DS; Letarte M
    Front Genet; 2015; 6():35. PubMed ID: 25717337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain arteriovenous malformation in hereditary hemorrhagic telangiectasia: Recent advances in cellular and molecular mechanisms.
    Drapé E; Anquetil T; Larrivée B; Dubrac A
    Front Hum Neurosci; 2022; 16():1006115. PubMed ID: 36504622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children.
    Hodgson J; Ruiz-Llorente L; McDonald J; Quarrell O; Ugonna K; Bentham J; Mason R; Martin J; Moore D; Bergstrom K; Bayrak-Toydemir P; Wooderchak-Donahue W; Morrell NW; Condliffe R; Bernabeu C; Upton PD
    Mol Genet Genomic Med; 2021 Dec; 9(12):e1685. PubMed ID: 33834622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced Endothelial Cell Cycle Arrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia.
    Genet G; Genet N; Paila U; Cain SR; Cwiek A; Chavkin NW; Serbulea V; Figueras A; Cerdà P; McDonnell SP; Sankaranarayanan D; Huba M; Nelson EA; Riera-Mestre A; Hirschi KK
    Circulation; 2024 Mar; 149(12):944-962. PubMed ID: 38126211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.